image credit: Unsplash

Back-to-back gene therapy approvals give Bluebird shot at survival

September 19, 2022

Until this August, just two gene therapies for inherited diseases were available in the U.S. Now, in the span of one month, that count has doubled, with the Food and Drug Administration approving new treatments for a rare blood condition and a childhood brain disorder.

The agency’s decisions, delivered Aug. 17 and on Friday, represent a turnaround for the gene therapy field after a series of setbacks had slowed progress. They also offer a lifeline to the treatments’ developer, the Massachusetts-based biotechnology company Bluebird bio, which is running out of money and earlier this year warned investors it may not be able to stay afloat.

Read More on Biopharma Dive